Shuiniujiao Dihuang Decoction With Variation for Psoriasis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2, randomized, placebo-controlled trial evaluates the effect of Shuiniujiao Dihuang Decoction with Variation (SDD) on adults with mild to moderate chronic plaque psoriasis. Participants are assigned to receive either the SDD regimen or a placebo for 12 weeks, with standard eligibility criteria including PASI 3–12 and no recent systemic psoriasis therapies. The study is conducted at the Hong Kong Institute of Integrative Medicine under the lead sponsorship of the Chinese University of Hong Kong. Traditional Chinese medicine principles guide inclusion and exclusion, alongside conventional safety monitoring, to assess clinical response and tolerability. Outcome measures will focus on changes in psoriasis severity and patient quality of life during the treatment period.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Mild to moderate chronic plaque psoriasis (PASI score 3 to 12).
* Willingness to give informed consent.

Exclusion Criteria:

* Pustular or generalized erythrodermic psoriasis.
* Psoriatic arthritis with syndrome of spleen-kidney yang deficiency according to Chinese medicine theory.
* Systemic therapy for psoriasis 6 months prior to baseline.
* Use topical medications for psoriasis 14 days prior to baseline such as retinoids, corticosteroids, vitamin D analogues, tazarotene and tacrolimus.
* Has taken any antibiotics, probiotics and prebiotics 30 days prior to baseline.
* UV light therapy 30 days prior to baseline.
* Clinically significant laboratory abnormality in blood, liver or renal functions (≥1.5 times the upper limit of reference range).
* History of allergy to Chinese herbs.
* Known pregnant or lactation, or have a plan to conceive in 6 months.
* Known active gastric or duodenal ulcer, or severe arrhythmia.
* Unwillingness to comply with study protocol.
* Any other condition that in the opinion of the investigators could disadvantage the subject.

Where it's running

• Hong Kong Institute of Integrative Medicine
  Hong Kong, Hong Kong Recruiting

Study contacts

• Principal investigator: Zhixiu LIN, PhD — Hong Kong Institute of Integrative Medicine
• Study coordinator: Zhixiu LIN, PhD
• Email: linzx@cuhk.edu.hk
• Phone: 852-3943 6347

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HRS-4139 safety and pharmacology in healthy adults

  This early-phase study tests a single dose of HRS-4139 to see if it is safe and how the body handles it in healthy adults aged 18–55.

  Recruiting Phase 1 Fujian Shengdi Pharmaceutical Co., Ltd. · Changsha, Hunan · NCT07802964

• Total Coumarin botanical cream for psoriasis vulgaris

  This trial will try a botanical Total Coumarin cream applied twice daily for 8 weeks to see if it helps adults with mild to moderate psoriasis.

  Recruiting Phase 3 Psoriasis Research Institute of Guangzhou · New York, New York · NCT07426120

• Topical diacerein in plaque psoriasis (adult) explores if a cream helps skin improve

  This trial tests whether applying a topical diacerein cream twice daily for 8 weeks helps adults with mild-to-moderate psoriasis vulgaris improve symptoms more than a placebo.

  Recruiting Phase 4 Cairo University · Cairo · NCT07352306

• Vaspin gene changes and blood vaspin levels in people with psoriasis

  This test will see if specific vaspin gene variants are linked to blood vaspin levels in people with psoriasis.

  Recruiting Aswan University · Aswān · NCT07320872

• Optimizing biologic dosing for psoriasis treatment

  This study is testing if a new way of adjusting psoriasis medication based on blood tests can work just as well as the usual method over 18 months.

  Recruiting at 10 sites Phase 4 University Hospital, Ghent · Bruges and 14 other locations · NCT06398106

• Treatment of psoriasis with deucravacitinib

  This study is testing how well a new medication called deucravacitinib can change immune cell behavior in people with moderate to severe psoriasis.

  Recruiting Phase 4 University of California, San Francisco · San Francisco, California · NCT05858645

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.